fbpx

molecules of the month

BMS-986242

oral IDO1 inhibitor

clinical candidate in Ph. I/II combo for cancer

reversed amide of linrodostat

ACS Med. Chem. Lett., Jan. 28, 2021

Bristol Myers Squibb, Lawrence Township, NJ

Chemical structure of molecule BMS-986242
1 min read

The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at this molecule since it’s so similar to linrodostat, which we covered recently. Forming the reverse amide of linrodostat appears to improve the PK profile and also removes a potential reactive aniline metabolite. Making the reverse amide of an amide starting point is a med. chem. tactic that’s often suggested, but it’s rare to see it play out so well, especially when both the amide H-bond donor and acceptor making interactions with the target.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: